Share on StockTwits

Regulus Therapeutics (NASDAQ:RGLS) Director Isis Pharmaceuticals Inc 4,500 shares of the company’s stock in a transaction that occurred on Thursday, July 10th. The was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Regulus Therapeutics (NASDAQ:RGLS) traded down 0.91% during mid-day trading on Friday, hitting $6.50. 40,353 shares of the company’s stock traded hands. Regulus Therapeutics has a 52-week low of $5.40 and a 52-week high of $12.42. The stock’s 50-day moving average is $7.32 and its 200-day moving average is $8.10. The company’s market cap is $281.8 million.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.30) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.14) by $0.16. On average, analysts predict that Regulus Therapeutics will post $-0.84 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on RGLS shares. Analysts at Zacks upgraded shares of Regulus Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Tuesday, June 17th. They now have a $7.80 price target on the stock. Finally, analysts at Brinson Patrick initiated coverage on shares of Regulus Therapeutics in a research note on Tuesday, May 13th. They set an “outperform” rating on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. Regulus Therapeutics has an average rating of “Buy” and a consensus price target of $14.76.

Regulus Therapeutics Inc, is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.